Skip to content

Industry

Healthcare

YMYL health content reviewed by medical professionals

YMYL health content reviewed by medical professionals. Provider, payer, health-tech, and digital therapeutic content engineered for both Google E-E-A-T and AI citation.

Category benchmarks

4 weeks

Typical medical reviewer turnaround in our network

100%

Of pages carry named medical reviewer byline by default

6-9 months

To establish category citation share in a new healthcare segment

Sub-verticals

Where we focus inside healthcare

Provider organizations

Hospital systems, multi-specialty groups, and direct-care providers. Service-line content, patient education, and provider-finder optimization.

Payer education

Health plans, ACO benefit communications, member portals, and broker-facing education. Plan-comparison content held to the same E-E-A-T bar as clinical content.

Health technology

SaaS for clinicians, RCM and practice-management vendors, AI diagnostic platforms. Buyers are physicians and administrators; the content has to respect both audiences.

Digital therapeutics and care delivery

Telehealth, prescription digital therapeutics, and condition-specific care platforms. The most challenging YMYL because clinical claims meet marketing scrutiny.

Health and wellness brands

Direct-to-consumer health, supplements, and wellness adjacent to healthcare. FTC and FDA implications even when the product is not regulated as a drug.

Health content held to health-content standards

Healthcare is the canonical YMYL category. Google’s Quality Rater Guidelines explicitly call it out as the area where E-E-A-T signals matter most. LLMs apply additional caution; ChatGPT and Claude both downweight medical content that lacks named clinical reviewers. The agencies that produce healthcare content at scale without abandoning medical rigor are rare. We built MediaWow’s healthcare practice around that exact gap.

How we work in healthcare

Every healthcare engagement starts with reviewer-network setup: clinical leads matched to your sub-vertical, with credentialing documented and bylines published. Drafts go through clinical review before editorial review. PHI is excluded from production workflows by default. Compliance review (when applicable) is built into the timeline, not bolted on at the end.

What we deliver

Editorial Compliance setup, GEO, expert-reviewed Editorial Production, Research and Data Studies (especially anonymized claims data and provider-survey work), and Digital PR into health and medical press. Healthcare clients commonly add Pipeline Diagnostics because the citation environment shifts faster than in other verticals.

What this category demands

Medical reviewer access

Building a roster of MD, NP, RN, RD, and PhD reviewers who will sign their names on production content is harder than any other YMYL category. The supply is constrained and the standards are personal.

HIPAA and PHI hygiene

Every case study, testimonial, or data study has to assume PHI is in the building. Compliance-aware production workflows are not optional.

FDA and FTC claim limits

What you can say about a product's efficacy depends on whether it is regulated as a drug, a device, a supplement, or none of the above. Content has to fit the claim envelope without losing its persuasive shape.

Clinical-evidence freshness

Guidelines update annually. Cited papers get retracted. Content that was accurate at publish can become misleading without a refresh cadence.

Regulatory context we work in (5 items)

  • HIPAA Privacy and Security Rules
  • FTC Endorsement Guides (health claims)
  • FDA labeling and claim rules (drugs, devices, supplements)
  • Stark Law and Anti-Kickback (provider organizations)
  • State medical board advertising rules

Listed for context. We collaborate with your compliance counsel; we do not replace it.